Aelis Farma Past Earnings Performance
Past criteria checks 0/6
Aelis Farma's earnings have been declining at an average annual rate of -32.6%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 9.1% per year.
Key information
-32.6%
Earnings growth rate
-27.3%
EPS growth rate
| Biotechs Industry Growth | 30.8% |
| Revenue growth rate | 9.1% |
| Return on equity | -70.7% |
| Net Margin | -65.2% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Aelis Farma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 11 | -7 | 3 | 15 |
| 31 Mar 24 | 12 | -6 | 3 | 16 |
| 31 Dec 23 | 12 | -5 | 3 | 16 |
| 30 Sep 23 | 11 | -5 | 2 | 15 |
| 30 Jun 23 | 10 | -6 | 2 | 14 |
| 31 Mar 23 | 9 | -10 | 3 | 14 |
| 31 Dec 22 | 8 | -14 | 3 | 14 |
| 30 Sep 22 | 8 | -14 | 3 | 12 |
| 30 Jun 22 | 7 | -14 | 3 | 11 |
| 31 Mar 22 | 9 | -6 | 2 | 9 |
| 31 Dec 21 | 11 | 1 | 1 | 7 |
| 30 Sep 21 | 10 | 2 | 1 | 6 |
| 30 Jun 21 | 9 | 3 | 1 | 5 |
| 31 Mar 21 | 5 | 1 | 1 | 4 |
| 31 Dec 20 | 1 | -2 | 1 | 3 |
| 31 Dec 19 | 0 | -3 | 1 | 0 |
| 31 Dec 18 | 0 | -3 | 1 | 0 |
| 31 Dec 17 | 0 | -1 | 1 | 0 |
Quality Earnings: AELIS is currently unprofitable.
Growing Profit Margin: AELIS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AELIS is unprofitable, and losses have increased over the past 5 years at a rate of 32.6% per year.
Accelerating Growth: Unable to compare AELIS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AELIS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).
Return on Equity
High ROE: AELIS has a negative Return on Equity (-70.68%), as it is currently unprofitable.